165 related articles for article (PubMed ID: 17971590)
1. Incidence of neuroblastoma after a screening program.
Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG
J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
3. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
4. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
[TBL] [Abstract][Full Text] [Related]
6. Treatment complications in children diagnosed with neuroblastoma during a screening program.
Barrette S; Bernstein ML; Leclerc JM; Champagne MA; Samson Y; Brossard J; Woods WG
J Clin Oncol; 2006 Apr; 24(10):1542-5. PubMed ID: 16575005
[TBL] [Abstract][Full Text] [Related]
7. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening.
Soderstrom L; Woods WG; Bernstein M; Robison LL; Tuchman M; Lemieux B
J Natl Cancer Inst; 2005 Aug; 97(15):1118-24. PubMed ID: 16077069
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma screening at one year of age.
Schilling FH; Spix C; Berthold F; Erttmann R; Fehse N; Hero B; Klein G; Sander J; Schwarz K; Treuner J; Zorn U; Michaelis J
N Engl J Med; 2002 Apr; 346(14):1047-53. PubMed ID: 11932471
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
10. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B; Brodeur GM
Eur J Cancer; 1997 Oct; 33(12):2106-12. PubMed ID: 9516863
[TBL] [Abstract][Full Text] [Related]
11. [Neuroblastoma in the Auvergne region from 1986 to 1991: epidemiological data].
Gembara P; Dechelotte P; Chazal J; Chauvin F; Chopard P; Goddon R; Goumy P; Masson A; Malpuech G; Deméocq F
Pediatrie; 1993; 48(11):801-4. PubMed ID: 8058441
[TBL] [Abstract][Full Text] [Related]
12. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
13. Compliance in a screening program for neuroblastoma.
Campion P; Woods WG; Lemieux B
Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953
[TBL] [Abstract][Full Text] [Related]
14. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.
Kitzmann AS; Pulido JS; Diehl NN; Hodge DO; Burke JP
Ophthalmology; 2008 Jan; 115(1):169-73. PubMed ID: 18166410
[TBL] [Abstract][Full Text] [Related]
15. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis neuroblastoma: is screening the answer?
Craft AW; Parker L
Br J Cancer Suppl; 1992 Aug; 18():S96-101. PubMed ID: 1503935
[TBL] [Abstract][Full Text] [Related]
17. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
18. Screening for neuroblastoma (NB) in North America: the Quebec Project.
Woods WG; Lemieux B; Leclerc JM; Bernstein ML; Brisson L; Brossard J; Brodeur GM; Look AT; Robison LL; Shuster JJ
Prog Clin Biol Res; 1994; 385():377-82. PubMed ID: 7972234
[No Abstract] [Full Text] [Related]
19. Lead-time and overdiagnosis estimation in neuroblastoma screening.
Spix C; Michaelis J; Berthold F; Erttmann R; Sander J; Schilling FH
Stat Med; 2003 Sep; 22(18):2877-92. PubMed ID: 12953286
[TBL] [Abstract][Full Text] [Related]
20. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
